These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 19951274)
1. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274 [TBL] [Abstract][Full Text] [Related]
2. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619 [TBL] [Abstract][Full Text] [Related]
3. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R; Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010 [TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798 [TBL] [Abstract][Full Text] [Related]
5. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489 [TBL] [Abstract][Full Text] [Related]
6. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534 [TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Leroi I; Brandt J; Reich SG; Lyketsos CG; Grill S; Thompson R; Marsh L Int J Geriatr Psychiatry; 2004 Jan; 19(1):1-8. PubMed ID: 14716693 [TBL] [Abstract][Full Text] [Related]
8. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369 [TBL] [Abstract][Full Text] [Related]
10. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895 [TBL] [Abstract][Full Text] [Related]
11. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Wesnes KA; McKeith I; Edgar C; Emre M; Lane R Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500 [TBL] [Abstract][Full Text] [Related]
12. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Farlow MR; Alva G; Meng X; Olin JT Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593 [TBL] [Abstract][Full Text] [Related]
13. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Darreh-Shori T; Jelic V Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Burns A; Spiegel R; Quarg P Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039 [TBL] [Abstract][Full Text] [Related]
20. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]